In response to industry demand, RoslinCT and Lykan Bioscience, a Contract Development and Manufacturing company for cell therapies, unveiled six new cGMP processing suites to their facility in Hopkinton, MA.

The completion of the expansion brings the global capacity to 22 cGMP suites with 14 in Hopkinton, and another eight in Edinburgh, Scotland.

The new processing suites will range from 105 to 525 square feet, including specific suites designed to meet both U.S. and EU regulatory requirements for clinical and commercial manufacturing.

As part of the expansion, an automated processing room is included and will be capable of accommodating a range of manufacturing platforms as well as allogeneic and autologous-based products.

“With this expansion, we will increase our capacity by 75% enabling us to meet the needs of a greater number of projects and their respective volume requirements,” said Patrick Lucy, President and CEO of Lykan Bioscience, “The state-of-the-art manufacturing facility and experienced Lykan team is poised to deliver across a number of cell platforms meeting both US and EU clinical and commercial regulatory requirements for cGMP manufacturing.”

Peter Coleman, CEO of RoslinCT, said: “This expansion builds on RoslinCT and Lykan’s expertise and marks another significant milestone in our collaboration. The additional capacity at Lykan’s facility in Hopkinton will allow us to continue delivering cutting-edge products, enabling our clients to offer life-changing therapies to patients around the world and meet the increasing demand for innovative therapies.”